Oncology Clinical Trials in Nashville, TN

As of September 2026, 401 paid clinical trials are recruiting for Oncology in Nashville, Tennessee. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 24, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

402 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in Nashville, TN.

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

for Ovarian Cancer

Drug: Bevacizumab

Sites in Nashville +31 more locations

Sponsor: Daiichi Sankyo

Sex: Female·Age: 18+

Code: NCT06819007·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

Sites in Nashville +25 more locations

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Galleri® in the Medicare Population.

for Cancer

Sites in Nashville, Brentwood +59 more locations

Sponsor: GRAIL, Inc.

Sex: All·Age: 50+·Accepts healthy volunteers

Code: NCT05673018·Recruiting·Listed Jan 2023

Apply to this trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for Multiple Myeloma

Drug: Elranatamab

Sites in Nashville +92 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06152575·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for Leukemia, Myeloid, Acute

Sites in Nashville +29 more locations

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 12+

Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

for Gastroesophageal-junction Cancer

Sites in Nashville +28 more locations

Sponsor: Shanghai Henlius Biotech

Sex: All·Age: 18+

Code: NCT06532006·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for Breast Cancer

Sites in Nashville, Germantown +111 more locations

Sponsor: Agendia

Sex: All·Age: 18+

Code: NCT03053193·Recruiting·Listed Feb 2017

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in Nashville +43 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

for Prostate Cancer

Sites in Nashville +28 more locations

Sponsor: Clarity Pharmaceuticals Ltd

Sex: Male·Age: 18+

Code: NCT06056830·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Sites in Nashville +37 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

Sites in Nashville, Chattanooga +56 more locations

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for Cancer, Metastatic

Sites in Nashville, Memphis +65 more locations

Sponsor: Massive Bio, Inc.

Sex: All·Age: All ages

Code: NCT03452774·Recruiting·Listed Mar 2018

Apply to this trial

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

for Advanced Solid Tumors

Sites in Nashville +27 more locations

Sponsor: DualityBio Inc.

Sex: All·Age: 18+

Code: NCT05914116·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

for AML

Sites in Nashville +25 more locations

Sponsor: TScan Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07702578·Phase 3·Recruiting·Listed Jul 2026

Apply to this trial

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for Pancreatic Cancer

Drug: Atebimetinib

Sites in Nashville, Germantown +38 more locations

Sponsor: Immuneering Corporation

Sex: All·Age: 18+

Code: NCT07562152·Phase 3·Recruiting·Listed May 2026

Apply to this trial

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for Pancreatic Cancer

Drug: daraxonrasib

Sites in Nashville +17 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07491445·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

for Myelodysplastic Syndrome

Sites in Nashville +30 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07422480·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

for Esophageal Squamous Cell Carcinoma

Sites in Nashville +14 more locations

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07503808·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

for NSCLC Adenocarcinoma

Sites in Nashville +19 more locations

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07277413·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer (NSCLC)

Sites in Nashville +18 more locations

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT07288177·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

for Ovarian Neoplasms

Sites in Nashville, Knoxville +24 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT07318558·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

for Lymphoma, Non-Hodgkin's

Drug: LY4584180

Sites in Nashville +20 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07226843·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

for Multiple Myeloma

Sites in Nashville +19 more locations

Sponsor: C4 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07284758·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

for Multiple Myeloma

Drug: Daratumumab

Sites in Nashville +16 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07095452·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

Drug: Giredestrant

Sites in Nashville +27 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

Drug: Osimertinib

Sites in Nashville, Knoxville +14 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07155187·Phase 2, Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Non Small Cell Lung Cancer

Drug: REGN7075

Sites in Nashville, Knoxville +14 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07154290·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

for Metastatic Breast Cancer

Sites in Nashville, Chattanooga +10 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT03424005·Phase 1, Phase 2·Recruiting·Listed Feb 2018

Apply to this trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for Bladder Cancer

Sites in Nashville +15 more locations

Sponsor: EvolveImmune United, Inc

Sex: All·Age: 18+

Code: NCT07217171·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

for Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Sites in Nashville, Memphis +21 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 100

Code: NCT05920356·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

for Lymphoma, Non-Hodgkin

Sites in Nashville +22 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07101328·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for Metastatic Gastric Adenocarcinoma

Sites in Nashville +18 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT07043400·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

Sites in Nashville +20 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07090499·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for Metastatic Solid Tumor

Drug: LY4052031

Sites in Nashville +20 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06465069·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

for Breast Cancer

Sites in Nashville +14 more locations

Sponsor: Terremoto Biosciences Inc.

Sex: All·Age: 18+

Code: NCT07109726·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Nashville +7 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06120283·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

for Breast Cancer

Sites in Nashville +15 more locations

Sponsor: Tempus AI

Sex: All·Age: 18 - 99

Code: NCT07211178·Recruiting·Listed Oct 2025

Apply to this trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

for Metastatic Solid Tumor

Sites in Nashville +15 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06561685·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

for Non-small Cell Lung Cancer

Sites in Nashville +21 more locations

Sponsor: Nuvalent Inc.

Sex: All·Age: 18+

Code: NCT06765109·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for Non-Small Cell Lung Cancer (NSCLC)

Drug: daraxonrasib

Sites in Nashville +19 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06128551·Phase 1, Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Conditions in Oncology (Nashville, TN)

Solid tumor· 105 Non-small cell lung cancer (NSCLC)· 68 Breast cancer· 47 Colorectal cancer· 41 Pancreatic cancer· 34 Ovarian cancer· 32 Head and neck cancer· 30 Cancer (any)· 30 Prostate cancer· 26 Endometrial cancer· 23 Multiple myeloma· 22 Metastatic breast cancer· 19 Gastric cancer· 18 Esophageal cancer· 18 Bladder cancer· 18 Acute myeloid leukemia (AML)· 17 Non-Hodgkin lymphoma· 16 Melanoma· 16 Metastatic prostate cancer· 15 Triple-negative breast cancer· 12 Cervical cancer· 12 Lung cancer· 11 Chronic lymphocytic leukemia (CLL)· 10 Myelodysplastic syndromes (MDS)· 10 Hematologic malignancy· 10 Small cell lung cancer· 9 Gastroesophageal junction cancer· 8 Leukemia (other)· 8 Small lymphocytic lymphoma· 8 Kidney cancer· 7 Metastatic colorectal cancer· 6 Colon cancer· 6 Biliary tract cancer· 6 HER2-negative breast cancer· 5 Fallopian tube cancer· 5 Diffuse large B-cell lymphoma (DLBCL)· 5 Follicular lymphoma· 5 Thyroid cancer· 5 Sarcoma· 5 Neuroblastoma· 5 Mesothelioma· 5 HER2-positive breast cancer· 4 Rectal cancer· 4 Glioma· 4 Myelofibrosis· 4 Mantle cell lymphoma· 4 Glioblastoma· 3 Brain cancer· 3 Chronic myelomonocytic leukemia· 3 Marginal zone lymphoma· 3 Osteosarcoma· 3 Ewing sarcoma· 3 Neuroendocrine tumors· 3 Liver cancer· 2 Uterine cancer· 2 Brain metastases· 2 Acute lymphoblastic leukemia· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Skin cancer· 2 Rhabdomyosarcoma· 2 Gastrointestinal cancer· 1 Burkitt lymphoma· 1